Using cooling to end brain damage during stroke.
Acquired by Penumbra (NYSE:PEN).
Key people at Voyage Biomedical.
Voyage Biomedical was founded in 2018 by Justin Olshavsky (Founder) and Bridget Vaughan (Founder) and Robert Schultz (Founder).
Voyage Biomedical was founded in 2018 by Justin Olshavsky (Founder) and Bridget Vaughan (Founder) and Robert Schultz (Founder).
Voyage Biomedical develops a medical device called the Voyage Brain Cooling System, designed to rapidly and selectively cool the brain to prevent or reduce brain damage caused by cerebral ischemia during stroke. By lowering brain temperature, the device slows metabolic processes, reduces oxygen demand, inflammation, and swelling, thereby improving stroke recovery outcomes. The company serves stroke patients and healthcare providers specializing in acute stroke care. Voyage Biomedical has gained momentum through clinical development and was acquired by Penumbra, a major medical device company, signaling strong growth and validation of its technology[1][3][4].
Voyage Biomedical was founded by a team including Ting and Marat, who combined engineering and clinical expertise to develop a novel brain cooling device. The idea emerged from research showing that selective brain hypothermia could protect brain tissue during ischemic stroke by reducing metabolic demand and inflammation. Early development focused on creating a device capable of delivering controlled cooling via a metallic tube system that generates cold air piped into the nostrils, regulated by a microprocessor controller to maintain therapeutic temperatures for extended periods. Clinical insights from Marat helped shape the device’s design and trial protocols, marking pivotal progress toward clinical application[2].
Voyage Biomedical rides the growing trend of neuroprotection and precision medicine in acute stroke care. Stroke remains a leading cause of disability and death worldwide, and current treatments have limitations in time windows and efficacy. Selective brain cooling addresses a critical unmet need by protecting brain tissue during ischemia, potentially expanding therapeutic options. Advances in medical device miniaturization, real-time monitoring, and targeted therapies create favorable market conditions. Voyage Biomedical’s technology influences the ecosystem by pushing innovation in non-pharmacological neuroprotection and integrating engineering with clinical practice for better patient outcomes[2][6].
Voyage Biomedical is poised to advance clinical adoption of brain cooling as a standard adjunct therapy for stroke, especially under Penumbra’s commercialization and distribution capabilities. Future trends shaping its journey include increasing emphasis on neuroprotective strategies, integration with stroke intervention devices, and potential expansion into other ischemic brain injury indications. As clinical evidence accumulates, the company’s influence may grow, driving broader acceptance of hypothermia-based treatments and inspiring further innovation in acute neurological care. The promise of reducing brain damage during stroke through controlled cooling represents a significant leap forward in improving patient recovery and quality of life[1][2][3].
Key people at Voyage Biomedical.
